CB-708

N/A

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameCB-708
Drug Alias NameCB-708CB708ATG-037ATN-037
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action5'-nucleotidase inhibitors
Targets5'-nucleotidase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCalithera Biosciences Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAntengene Corp LtdDeli (Zhejiang) Pharmaceutical Co LtdAntengene Therapeutics Ltd +[5] 
Inactive CompaniesAntengene Corporation Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A